Breast cancer study highlights promising efficacy of T-DM1 after pertuzumab
A study has found that patients with HER2-positive breast cancer, who have relapsed after initial combination therapy with pertuzumab, can respond well to T-DM1 as a second line treatment; demonstrating the value of continued anti-HER2 treatment.Bernedetta Conte, from the University of Genoa, Italy, is the first author of the study, which was published recently in Clinical Breast Cancer. Her team investigated the efficacy of T-DM1 as a second-line treatment in HER2-positive breast cancer patients. She presented the results at the Advanced Breast Cancer Fifth International Consensus Conference (14–16 November, Lisbon, Portugal). In this study, 77 eligible patients were identified. This...